Experienced Medtronic Executive to Lead Clinical and Commercial Efforts

Versa Vascular, a privately held medical device company, has appointed Bill Shields as its new CEO. Shields brings 15 years of experience from Medtronic (MDT), where he led the structural heart disease business. He will oversee AdapTR's U.S. clinical and regulatory strategy, leveraging his expertise in transcatheter mitral and tricuspid valve therapies. Former CEO David Hoppin will remain as an advisor to support the ongoing development. The appointment of an executive with commercialization experience signals a shift in focus towards FDA clinical trials and manufacturing scale-up, rather than early-stage technology development.

AdapTR: An Investigational Device for Preserving Natural Heart Valves

AdapTR is a transcatheter tricuspid valve repair device designed to treat severe tricuspid regurgitation without replacing the native valve. The device is currently in clinical trials, with the initial phase involving first-in-human studies and preparations for a U.S. early feasibility study. AdapTR consists of a nitinol frame and a central disc positioned in the right atrium. This design aims to stabilize the valve annulus, reduce regurgitant flow, and preserve the function of the native valve leaflets. The device is delivered via a 26-French delivery catheter and allows for repositioning before final deployment, simplifying procedural control and facilitating image guidance. NCT06368401, a single-arm study involving 10 patients with severe tricuspid regurgitation who are not suitable for surgery, began in August 2024. Initial results in the first patient showed a reduction in regurgitation and improvement in functional status up to 90 days.

Series C Extension Provides Capital for U.S. Clinical Trials

The company has secured a total of $42.3 million in equity financing through an extension of its existing Series C round, adding $15 million to the initial $27.3 million. The funds will be used to complete the ongoing first-in-human studies outside the U.S. and initiate the FDA early feasibility study. The financing does not include any upfront payments or conditional milestones. For early-stage medical device companies, patient enrollment, long-term follow-up, clinical manufacturing, and the establishment of a quality system represent significant cash expenditures. This extension will enhance the company's ability to achieve key regulatory milestones.

AdapTR Must Demonstrate Differentiation in Clinical Trials

The primary competing products in the U.S. market are Abbott Laboratories' (ABT) TriClip G4 transcatheter edge-to-edge repair (TEER) system and Edwards Lifesciences' (EW) EVOQUE transcatheter valve replacement. The FDA approved EVOQUE on February 1, 2024, and TriClip on April 2, 2024, and both products are now commercially available. Unlike TriClip, which grasps the valve leaflets, or EVOQUE, which replaces the valve, AdapTR is an atrial implant that aims to control both the valve annulus and the regurgitant flow. However, AdapTR is not yet approved. The global tricuspid valve repair market is projected to grow from $663.69 million in 2025 to $957.96 million in 2031, and there are approximately 1.6 million patients in the U.S. who could benefit from this therapy.